SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
10-Q
(Mark
One)
x QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
For the
quarterly period ended December 31, 2008
OR
o TRANSACTION REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
For the
transition period from _______ to _______
COMMISSION
FILE NO. 0-17629
ADM
TRONICS UNLIMITED, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
22-1896032
|
(State
or Other Jurisdiction
|
(I.R.S.
Employer
|
of
Incorporation or organization)
|
Identification
Number)
|
224-S
Pegasus Ave., Northvale, New Jersey 07647
(Address
of Principal Executive Offices)
Registrant's
Telephone Number, including area code: (201) 767-6040
Indicate by check mark whether the
Registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the Registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days:
YES x NO o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act.
Large
accelerated filer o
|
Accelerated
filer o
|
|
|
Non-accelerated
filer o
(Do not check if a smaller reporting company)
|
Smaller
reporting company x
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
YES o NO x
State the
number of shares outstanding of each of the Issuer's classes of common equity,
as of the latest practicable date:
53,939,537
shares of Common Stock, $.0005 par value, as of February 16, 2009
ADM
TRONICS UNLIMITED, INC.
INDEX
|
|
Page
Number
|
PART
I.
|
FINANCIAL
INFORMATION
|
|
|
|
|
ITEM
1.
|
CONSOLIDATED
FINANCIAL STATEMENTS:
|
|
|
|
|
|
Condensed
Consolidated Balance Sheets – December 31, 2008 (unaudited) and March 31,
2008
|
3
|
|
|
|
|
Condensed
Consolidated Statements of Operations – For the three and nine months
ended December 31, 2008 and 2007 (unaudited)
|
4
|
|
|
|
|
Condensed
Consolidated Statements of Cash Flows – For the nine months ended December
31, 2008 and 2007 (unaudited)
|
5
|
|
|
|
|
Notes
to Condensed Consolidated Financial Statements (unaudited)
|
6
|
|
|
|
ITEM
2.
|
MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
11
|
|
|
|
ITEM
3.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
13
|
|
|
|
ITEM
4T.
|
CONTROLS
AND PROCEDURES
|
13
|
|
|
|
PART
II. OTHER INFORMATION
|
|
|
|
ITEM
1.
|
LEGAL
PROCEEDINGS
|
14
|
|
|
|
ITEM
1A.
|
RISK
FACTORS
|
14
|
|
|
|
ITEM
2.
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
14
|
|
|
|
ITEM
3.
|
DEFAULTS
UPON SENIOR SECURITIES
|
14
|
|
|
|
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
14
|
|
|
|
ITEM
5.
|
OTHER
INFORMATION
|
14
|
|
|
|
ITEM
6.
|
EXHIBITS
|
14
|
ITEM
1. CONSOLIDATED FINANCIAL STATEMENTS
ADM
TRONICS UNLIMITED, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
|
DECEMBER
31, 2008
|
|
|
MARCH
31, 2008
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$ |
1,325,511 |
|
|
$ |
2,072,325 |
|
Accounts
receivable, net of allowance for doubtful
|
|
|
|
|
|
|
|
|
accounts
of $1,088 and $1,088, respectively
|
|
|
103,990 |
|
|
|
101,270 |
|
Inventories
|
|
|
338,250 |
|
|
|
469,403 |
|
Prepaid
expenses and other current assets
|
|
|
7,311 |
|
|
|
83,731 |
|
Restricted
cash
|
|
|
225,650 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Total
current assets
|
|
|
2,000,712 |
|
|
|
2,726,729 |
|
|
|
|
|
|
|
|
|
|
Property
and equipment, net of accumulated depreciation
|
|
|
|
|
|
|
|
|
of
$24,829 and $17,873, respectively
|
|
|
63,220 |
|
|
|
55,288 |
|
|
|
|
|
|
|
|
|
|
Inventory
- long term portion
|
|
|
84,099 |
|
|
|
78,416 |
|
Investment
in Ivivi
|
|
|
910,000 |
|
|
|
2,154,517 |
|
Advances
to related parties
|
|
|
50,843 |
|
|
|
74,299 |
|
Other
assets
|
|
|
225,452 |
|
|
|
28,486 |
|
|
|
|
|
|
|
|
|
|
Total
assets
|
|
$ |
3,334,326 |
|
|
$ |
5,117,735 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$ |
120,801 |
|
|
$ |
237,331 |
|
Note
payable – Bank
|
|
|
200,000 |
|
|
|
-- |
|
Accrued
expenses and other current liabilities
|
|
|
48,698 |
|
|
|
87,439 |
|
Customer
deposits – Ivivi
|
|
|
108,097 |
|
|
|
241,828 |
|
|
|
|
|
|
|
|
|
|
Total
current liabilities
|
|
|
477,596 |
|
|
|
566,598 |
|
|
|
|
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
|
|
|
|
Preferred
stock, $.01 par value; 5,000,000 shares authorized,
|
|
|
|
|
|
|
|
|
no
shares issued and outstanding
|
|
|
-- |
|
|
|
-- |
|
Common
stock, $.0005 par value; 150,000,000 shares
|
|
|
|
|
|
|
|
|
authorized,
53,939,537 shares issued and outstanding at
|
|
|
|
|
|
|
|
|
December
31, 2008 and March 31, 2008
|
|
|
26,970 |
|
|
|
26,970 |
|
Additional
paid-in capital
|
|
|
32,153,597 |
|
|
|
32,153,597 |
|
Accumulated
deficit
|
|
|
(29,323,837 |
) |
|
|
(27,629,430 |
) |
|
|
|
|
|
|
|
|
|
Total
stockholders' equity
|
|
|
2,986,730 |
|
|
|
4,551,137 |
|
|
|
|
|
|
|
|
|
|
Total
liabilities and stockholders' equity
|
|
$ |
3,334,326 |
|
|
$ |
5,117,735 |
|
The
accompanying notes are an integral part of these unaudited
condensed
consolidated financial statements.
ADM
TRONICS UNLIMITED, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE
THREE AND NINE MONTHS ENDED DECEMBER 31, 2008 AND 2007
(Unaudited)
|
|
Three
Months Ended
|
|
|
Nine
Months Ended
|
|
|
|
December
31,
|
|
|
December
31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$ |
257,610 |
|
|
$ |
496,261 |
|
|
$ |
1,248,140 |
|
|
$ |
1,189,194 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs
and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
of sales
|
|
|
183,355 |
|
|
|
352,942 |
|
|
|
840,835 |
|
|
|
772,171 |
|
Research
and development
|
|
|
- |
|
|
|
115 |
|
|
|
- |
|
|
|
3,665 |
|
Selling,
general and administrative
|
|
|
291,791 |
|
|
|
273,691 |
|
|
|
892,372 |
|
|
|
768,208 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating expenses
|
|
|
475,146 |
|
|
|
626,748 |
|
|
|
1,733,207 |
|
|
|
1,544,044 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(217,536 |
) |
|
|
(130,487 |
) |
|
|
(485,067 |
) |
|
|
(354,850 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income, net
|
|
|
6,537 |
|
|
|
21,576 |
|
|
|
35,178 |
|
|
|
72,366 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
in fair value of investment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
in
Ivivi
|
|
|
(650,000 |
) |
|
|
- |
|
|
|
(10,465,000 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
in net loss of Ivivi
|
|
|
- |
|
|
|
(594,446 |
) |
|
|
- |
|
|
|
(1,674,870 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss before income tax benefit
|
|
|
(860,999 |
) |
|
|
(681,348 |
) |
|
|
(10,914,889 |
) |
|
|
(1,957,354 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
tax benefit
|
|
|
|
|
|
|
-- |
|
|
|
2,425,188 |
|
|
|
-- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$ |
(860,999 |
) |
|
$ |
(703,357 |
) |
|
$ |
(8,489,701 |
) |
|
$ |
(1,957,354 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss per share, basic and diluted
|
|
$ |
(0.02 |
) |
|
$ |
(0.01 |
) |
|
$ |
(0.16 |
) |
|
$ |
(0.04 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average shares outstanding,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
basic
and diluted
|
|
|
53,939,537 |
|
|
|
53,882,037 |
|
|
|
53,939,537 |
|
|
|
53,882,037 |
|
The
accompanying notes are an integral part of these unaudited
condensed
consolidated financial statements.
ADM
TRONICS UNLIMITED, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE
NINE MONTHS ENDED DECEMBER 31, 2008 AND 2007
(Unaudited)
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
Net
loss
|
|
$ |
(8,489,701 |
) |
|
$ |
(1,957,354 |
) |
Adjustments
to reconcile net loss to net cash
|
|
|
|
|
|
|
|
|
used
by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
22,479 |
|
|
|
12,461 |
|
Deferred
income tax benefit
|
|
|
(2,425,188 |
) |
|
|
-- |
|
Loss
from equity investment
|
|
|
|
|
|
|
1,674,870 |
|
Interest
accrued on officer loan
|
|
|
-- |
|
|
|
(1,107 |
) |
Change
in fair value of investment in Ivivi
|
|
|
10,465,000 |
|
|
|
-- |
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
(Increase)
decrease in:
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(2,720 |
) |
|
|
(24,231 |
) |
Inventory
|
|
|
125,470 |
|
|
|
(484,418 |
) |
Prepaid
expenses and other current assets
|
|
|
76,420 |
|
|
|
27,875 |
|
Other
assets
|
|
|
-- |
|
|
|
34,003 |
|
Increase
(decrease) in:
|
|
|
|
|
|
|
|
|
Accounts
payable and accrued expenses
|
|
|
(155,270 |
) |
|
|
89,911 |
|
Customer
deposit – Ivivi
|
|
|
(133,731 |
) |
|
|
323,444 |
|
|
|
|
|
|
|
|
|
|
Net
cash used by operating activities
|
|
|
(517,241 |
) |
|
|
(304,546 |
) |
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Purchases
of property and equipment
|
|
|
(14,888 |
) |
|
|
(22,140 |
) |
Collections
of advances to related parties
|
|
|
23,456 |
|
|
|
20,000 |
|
Acquired
intangible assets
|
|
|
(212,491 |
) |
|
|
-- |
|
Deposit
– restricted cash
|
|
|
(225,650 |
) |
|
|
-- |
|
|
|
|
|
|
|
|
|
|
Net
cash used by investing activities
|
|
|
(429,573 |
) |
|
|
(2,140 |
) |
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Proceeds
from note payable – Bank
|
|
|
200,000 |
|
|
|
-- |
|
|
|
|
|
|
|
|
|
|
Net
decrease in cash
|
|
|
(746,814 |
) |
|
|
(306,686 |
) |
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents, beginning of period
|
|
|
2,072,325 |
|
|
|
2,498,276 |
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents, end of period
|
|
$ |
1,325,511 |
|
|
$ |
2,191,590 |
|
|
|
|
|
|
|
|
|
|
Cash
paid for:
|
|
|
|
|
|
|
|
|
Interest
|
|
$ |
2,677 |
|
|
$ |
-- |
|
Income
taxes
|
|
$ |
-- |
|
|
$ |
4,060 |
|
|
|
|
|
|
|
|
|
|
NONCASH
FINANCING AND INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
During
the nine months ended December 31, 2007, Ivivi recorded an increase
in
|
|
|
|
|
|
|
|
|
additional
paid-in capital as a result of the recognition of
compensation
|
|
|
|
|
|
|
|
|
expense
related to option grants to employees and others. We have recorded
a
|
|
|
|
|
|
|
|
|
proportional
increase in our investment in Ivivi in the amount of $410,558,
with
|
|
|
|
|
|
|
|
|
a
related credit to additional paid-in capital. We have also recorded a
change
|
|
|
|
|
|
|
|
|
of
ownership percentage adjustment of $1,259,542.
|
|
|
|
|
|
|
|
|
The
accompanying notes are an integral part of these unaudited
condensed
consolidated financial statements.
ADM
TRONICS UNLIMITED, INC. AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2008
(Unaudited)
NOTE
1 - ORGANIZATIONAL MATTERS
ADM
Tronics Unlimited, Inc. ("we", "us", the “Company" or "ADM"), was incorporated
under the laws of the state of Delaware on November 24, 1969. We are
authorized under our Certificate of Incorporation to issue 150,000,000 common
shares, with $.0005 par value, and 5,000,000 preferred shares with $.01 par
value.
The
accompanying condensed consolidated financial statements as of December 31, 2008
(unaudited) and March 31, 2008 and for the three and nine month periods ended
December 31, 2008 and 2007 (unaudited) have been prepared by ADM pursuant to the
rules and regulations of the Securities and Exchange Commission (the “SEC”),
including Form 10-Q and Regulation S-X. The information furnished
herein reflects all adjustments (consisting of normal recurring accruals and
adjustments), which are, in the opinion of management, necessary to fairly
present the operating results for the respective periods. Certain
information and footnote disclosures normally present in annual financial
statements prepared in accordance with accounting principles generally accepted
in the United States of America have been omitted pursuant to such rules and
regulations. We believe that the disclosures provided are adequate to
make the information presented not misleading. These financial
statements and the information included under the heading "Management's
Discussion and Analysis of Financial Condition and Results of Operations" should
be read in conjunction with the audited financial statements and explanatory
notes for the year ended March 31, 2008 as disclosed in our Annual Report on
Form 10-KSB for that year as filed with the SEC, as it may be
amended. The results of the three and nine months ended December 31,
2008 (unaudited) are not necessarily indicative of the results to be expected
for the pending full year ending March 31, 2009.
NATURE
OF BUSINESS
We are a
manufacturing and engineering concern whose principal lines of business are the
production and sale of chemical products and the manufacture and sale of
electronics. On August 27, 2008, we acquired all of the assets of
Action Spas, a manufacturer of electronic controllers for spas and hot tubs,
under our fully owned subsidiary Action Industries Unlimited, LLC
(“Action”). With this acquisition, our previous Medical segment was
redefined as our Electronics segment, and the ongoing operations of Action are
now reported under this segment.
Our
Chemical segment is principally comprised of water-based chemical products, used
in the food packaging and converting industries. Our Electronics
segment primarily consists of contract manufacturing of electronic devices in
accordance with customer specifications and electronic controllers for spas and
hot tubs. To a lesser extent, our electronics product line also includes certain
proprietary electronic devices used in the treatment of joint pain,
postoperative edema, and tinnitus. All of our products are sold to
customers located in the United States, Australia, Asia and Europe.
NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES
CONSOLIDATION
The
consolidated financial statements include the accounts of ADM Tronics Unlimited,
Inc. and its subsidiaries. All significant intercompany balances and
transactions have been eliminated in consolidation.
USE
OF ESTIMATES
These
financial statements have been prepared in accordance with accounting principles
generally accepted in the United States and, accordingly, require management to
make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Significant
estimates made by management include expected economic life and value of our
medical devices, deferred tax assets, option and warrant expenses related to
compensation to employees and directors, consultants and investment banks, the
value of warrants issued in conjunction with convertible debt, allowance for
doubtful accounts, and warranty reserves. Actual results could differ from those
estimates.
FAIR
VALUE OF FINANCIAL INSTRUMENTS
On April
1, 2008, the Company adopted Statement of Financial Accounting Standards
(“SFAS”) No. 157, “Fair Value Measurements” and SFAS No. 159, “The Fair Value
Option for Financial Assets and Financial Liabilities”. Please refer
to Notes 4 , 5 and 10 for additional details. For certain of our
financial instruments, including accounts receivable, inventories, notes
payable, accounts payable and accrued expenses, the carrying amounts approximate
fair value due to their relatively short maturities.
CASH
AND EQUIVALENTS
Cash
equivalents are comprised of certain highly liquid investments with maturity of
three months or less when purchased. We maintain our cash in bank deposit
accounts, which at times, may exceed federally insured limits. We have not
experienced any losses to date as a result of this policy.
REVENUE
RECOGNITION
CHEMICALS:
Revenues
are recognized when products are shipped to end users. Shipments to
distributors are recognized as sales where no right of return
exists.
ELECTRONICS:
We
recognize revenue from the sale of our electronic products when they are shipped
to the purchaser. Revenue from the sale of the electronics we
manufacture for Ivivi is recognized upon completion of the manufacturing
process. Shipping and handling charges and costs are immaterial. We
offer a limited 90 day warranty on our electronics products and a limited 5 year
warranty on our electronic controllers for spas and hot tubs. We have
no other post shipment obligations and sales returns have been
immaterial.
ADVERTISING
COSTS
Advertising costs are expensed as
incurred and amounted to approximately $4,739 and $5,059 for the three months
ended December 31, 2008 and 2007 respectively, and $19,049 and $21,586 for the
nine months ended December 31, 2008 and 2007, respectively.
WARRANTY
LIABILITIES
We offer a limited 90 day warranty on
our electronics products and a 5 year limited warranty on all of our electronic
controllers for spas and hot tubs sold through Action. This product
lines’ past experience has resulted in immaterial costs associated with warranty
issues. Therefore, no warranty liabilities have yet been recorded.
RESTRICTED
CASH
Restricted
cash represents funds on deposit with a financial institution that secure our
note payable.
NET
LOSS PER SHARE
We use
SFAS No. 128, "Earnings Per Share" for calculating basic and diluted loss per
share. We compute basic loss per share by dividing net loss by the
weighted average number of common shares outstanding. Diluted loss
per share is computed similar to basic loss per share, except that the
denominator is increased to include the number of additional common shares that
would have been outstanding if the potential shares had been issued and if the
additional shares were dilutive. Common equivalent shares are
excluded from the computation of net loss per share if their effect is
anti-dilutive.
Per share
basic and diluted net loss amounted to $0.02 and $0.01, and $0.16 and $0.04, for
the three and nine months ended December 31, 2008 and 2007,
respectively. The assumed exercise of common stock equivalents was
not utilized for the nine month periods ended December 31, 2008 and 2007,
because the effect would be anti-dilutive. There were 11,626,854
common stock equivalents at December 31, 2008 and 2007.
RECENT
ACCOUNTING PRONOUNCEMENTS
On
October 10, 2008, the FASB issued Staff Position (“FSP”) FAS 157-3, Determining
the Fair Value of a Financial Asset When the Market for That Asset Is Not
Active. This FSP clarifies the application of FASB Statement No. 157,
Fair Value Measurements, in a market that is not active and provides an example
to illustrate key considerations in determining the fair value of a financial
asset when the market for that financial asset is not active. We have
completed our evaluation of the impact of the effect of the adoption of FSP FAS
157-3, and have determined it would have no impact on the Company's financial
position, results of operations or cash flows.
Management
does not believe that any other recently issued, but not yet effective
accounting pronouncements, if adopted, would have a material effect on the
accompanying financial statements.
NOTE
3 - INVENTORY
Inventory
at December 31, 2008 (unaudited) consists of the following:
|
|
Current
|
|
|
Long
Term
|
|
|
Total
|
|
Raw
materials
|
|
$ |
284,680 |
|
|
$ |
45,462 |
|
|
$ |
330,142 |
|
Finished
goods
|
|
|
53,570 |
|
|
|
38,636 |
|
|
|
92,206 |
|
|
|
$ |
338,250 |
|
|
$ |
84,099 |
|
|
$ |
422,349 |
|
Inventory
at March 31, 2008 consists of the following:
|
|
Current
|
|
|
Long
Term
|
|
|
Total
|
|
Raw
materials
|
|
$ |
361,897 |
|
|
$ |
39,186 |
|
|
$ |
401,083 |
|
Finished
goods
|
|
|
107,506 |
|
|
|
39,230 |
|
|
|
146,736 |
|
|
|
$ |
469,403 |
|
|
$ |
78,416 |
|
|
$ |
547,819 |
|
NOTE
4 - INVESTMENT IN IVIVI
Our
former majority owned subsidiary, Ivivi Technologies, Inc. (“Ivivi”), filed a
Registration Statement with the Securities and Exchange Commission for the
initial public offering of a portion of its common stock. The
Registration Statement was declared effective by the SEC on October 18,
2006. As a result of the consummation of Ivivi's initial public
offering, we no longer owned a majority of the outstanding common stock of
Ivivi. Since October 18, 2006, we could exert significant influence
based upon the percentage of Ivivi's stock we owned. As a result, our
investment in Ivivi was reported during the period from October 18, 2006 until
March 31, 2008 under the equity method of accounting, whereby we recognized our
share of Ivivi's earnings or losses as they are incurred. Effective
April 1, 2008 (“the Adoption Date”), we have adopted SFAS No. 159 “The Fair
Value Option for Financial Assets and Liabilities” with respect to our
investment in Ivivi, whereby we report our investment in Ivivi at fair
value. Management’s reason for electing the fair value option for its
investment in Ivivi is to increase the efficiency of our financial reporting
responsibilities. The fair value of our investment in Ivivi at the
adoption date was approximately $11,375,000. The adoption of SFAS No.
159, with respect to our investment in Ivivi, resulted in the recognition of the
following:
Pre-tax
cumulative-effect adjustment to retained earnings:
|
|
$ |
9,220,483 |
|
Deferred
tax liability:
|
|
|
2,425,188 |
|
|
|
|
|
|
Post-tax
cumulative-effect adjustment to retained earnings:
|
|
$ |
6,795,295 |
|
As of
December 31, 2008, the fair value of our investment in Ivivi was
$910,000. Our common shares of Ivivi have not been registered with
the SEC and are subject to restriction as a result of securities
laws. Subsequent to the date of our financial statements, the fair
value of our investment in Ivivi had decreased and Ivivi’s ability to continue
as a going concern is unknown.
The
following table sets forth summarized results of operations of Ivivi for the
nine months ended December 31, 2008 and 2007:
|
|
Nine
Months Ended
|
|
|
Nine
Months Ended
|
|
|
|
December
31, 2008
|
|
|
December
30, 2007
|
|
|
|
unaudited)
|
|
|
(unaudited)
|
|
Revenue
|
|
$ |
1,253,204 |
|
|
$ |
1,080,347 |
|
Costs
and expenses, net
|
|
|
7,143,144 |
|
|
|
6,350,824 |
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$ |
(5,589,940 |
) |
|
$ |
(5,270,477 |
) |
|
|
|
|
|
|
|
|
|
Assets
at December 31, 2008
|
|
$ |
3,453,986 |
|
|
|
|
|
Liabilities
at December 31, 2008
|
|
|
1,194,299 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
at December 31, 2008
|
|
$ |
2,259,687 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
at December 31, 2007
|
|
$ |
10,524,264 |
|
|
|
|
|
Liabilities
at December 31, 2007
|
|
|
1,534,307 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
at December 31, 2007
|
|
$ |
8,989,957 |
|
|
|
|
|
NOTE
5 – FAIR VALUE MEASUREMENTS
In
September 2006, the FASB issued Statement of Financial Accounting Standards
No. 157, “Fair Value Measurements” (“Statement No. 157”) which defines
fair value, establishes a framework for measuring fair value, and expands
disclosures about fair value measurements. Statement No. 157 applies to
other accounting pronouncements that require or permit fair value measurements
and does not require any new fair value measurements.
In
February 2008, the FASB issued FASB Staff Position 157-2, which provides
for a one-year deferral of the provisions of Statement No. 157 for
non-financial assets and liabilities that are recognized or disclosed at fair
value in the consolidated financial statements on a non-recurring basis. The
Company is currently evaluating the impact of adopting the provisions of
Statement No. 157 for non-financial assets and liabilities that are
recognized or disclosed on a non-recurring basis.
Effective
April 1, 2008, the Company adopted the provisions of Statement No. 157
for financial assets and liabilities, as well as for any other assets and
liabilities that are carried at fair value on a recurring basis. The adoption of
the provisions of Statement No. 157 related to financial assets and
liabilities and other assets and liabilities that are carried at fair value on a
recurring basis did not materially impact the Company’s consolidated financial
position and results of operations.
Statement
No. 157 defines fair value as the exchange price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or
most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. Statement No. 157 also
establishes a fair value hierarchy, which requires an entity to maximize the use
of observable inputs and minimize the use of unobservable inputs when measuring
fair value. Statement No. 157 describes three levels of inputs that may be
used to measure fair value:
Level
1
|
Unadjusted
quoted prices in active markets that are accessible at the measurement
date for identical, unrestricted assets or liabilities.
|
|
|
Level
2
|
Quoted
prices in markets that are not active; or other inputs that are
observable, either directly or indirectly, for substantially the full term
of the asset or liability.
|
|
|
Level
3
|
Prices
or valuation techniques that require inputs that are both significant to
the fair value measurement and
unobservable.
|
The
following table presents assets/(liabilities) measured at fair value on a
recurring basis at December 31, 2008:
|
|
Level
1
|
|
|
Level
2
|
|
|
Level
3
|
|
Investment
in Ivivi
|
|
$ |
910,000 |
|
|
$ |
-- |
|
|
$ |
-- |
|
NOTE
6 - CONCENTRATIONS
During
the three month period ended December 31, 2008, four customers accounted for
approximately 60% of our revenue. As of December 31, 2008, two
customers represented approximately 68% of our accounts receivable.
During
the three month period ended December 31, 2007, Ivivi accounted for
approximately 52% of our revenue, and one other customer accounted for
approximately 11% of our revenue. As of December 31, 2007, four
customers represented approximately 73% of our accounts receivable.
During
the nine month period ended December 31, 2008, Ivivi accounted for approximately
43% of our revenue, and one other customer accounted for approximately 14% or
our revenue.
During
the nine month period ended December 31, 2007, Ivivi accounted for approximately
40% of our revenue, and two other customers accounted for approximately 21% of
our revenue.
NOTE
7 - SEGMENT INFORMATION
Information
about segments is as follows:
|
|
Chemical
|
|
|
Electronics
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
Three
months ended December 31, 2008
|
|
|
|
|
|
|
|
|
|
Revenues
from external customers
|
|
$ |
182,670 |
|
|
$ |
74,940 |
|
|
$ |
257,610 |
|
Segment
operating (loss)
|
|
|
(85,260 |
) |
|
|
(132,276 |
) |
|
|
(217,536 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
months ended December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
from external customers
|
|
$ |
209,031 |
|
|
$ |
287,230 |
|
|
$ |
496,261 |
|
Segment
operating profit (loss)
|
|
|
9,717 |
|
|
|
(140,204 |
) |
|
|
(130,487 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine
months ended December 31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
from external customers
|
|
$ |
604,019 |
|
|
$ |
644,121 |
|
|
$ |
1,248,140 |
|
Segment
operating (loss)
|
|
|
(201,860 |
) |
|
|
(283,207 |
) |
|
|
(485,067 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine
months ended December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
from external customers
|
|
$ |
652,719 |
|
|
$ |
536,475 |
|
|
$ |
1,189,194 |
|
Segment
operating (loss)
|
|
|
(249,133 |
) |
|
|
(105,717 |
) |
|
|
(354,850 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
assets at December 31, 2008
|
|
$ |
2,543,894 |
|
|
$ |
790,432 |
|
|
$ |
3,334,326 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
assets at March 31, 2008
|
|
$ |
4,592,031 |
|
|
$ |
525,704 |
|
|
$ |
5,117,735 |
|
NOTE
8 - RELATED PARTY TRANSACTIONS
ADVANCES
TO RELATED PARTIES
As of
December 31, 2008 and March 31, 2008, ADM was owed $50,843 and $74,299,
respectively, from advances including accrued interest made to an officer and to
an officer and his wife. No advances have been made since
2000. The advances bear interest at an effective rate of
approximately 1% per year. Interest expense for the nine months ended
December 31, 2008 and 2007 was $631 and $1,146, respectively.
MANAGEMENT
SERVICES AGREEMENT
ADM
entered into a management services agreement with Ivivi, as of August 15, 2001,
as amended, under which ADM provides Ivivi with management services and
allocates portions of its real property facilities for use by Ivivi for the
conduct of its business. The management
services
provided by ADM under the management services agreement include managerial and
administrative services, marketing and sales services, clerical and
communication services, the maintenance of a checking account and the writing of
checks, the maintenance of accounting records and other services in the ordinary
course of business. Ivivi pays ADM for such services on a monthly basis pursuant
to an allocation determined by ADM and Ivivi based on a portion of its
applicable costs plus any invoices it receives from third parties specific to
Ivivi. ADM and Ivivi also use office, manufacturing and storage space in a
building located in Northvale, New Jersey, currently leased by ADM, pursuant to
the terms of the management services agreement. ADM determines the portion of
space allocated to Ivivi on a monthly basis, and Ivivi is required to reimburse
ADM for its portion of the lease costs, real property taxes and related
costs.
During
the three months ended December 31, 2008 and December 31, 2007, Ivivi had
$10,809 and $55,781, respectively, in management services provided to it by ADM
pursuant to the management services agreement. During the nine months
ended December 31, 2008 and December 31, 2007, Ivivi had $36,695 and $171,646,
respectively, in management services provided to it by ADM pursuant to the
management services agreement.
INFORMATION
TECHNOLOGY SERVICE AGREEMENT
ADM
entered into an information technology (“IT”) service agreement with Ivivi on
February 1, 2008, pursuant to which Ivivi, in conjunction with its outside IT
professionals, will service ADM’s IT needs on an as needed
basis. Ivivi will invoice ADM monthly for any time it spends in
providing such services to ADM. The rate that Ivivi will charge ADM will be
determined at date of invoice. Such invoices that Ivivi issues ADM, with respect
to such services, will be due within 30 days. IT services include, but are not
limited to: computer hardware and software related issues, network
administration, e-mail hosting and administration, telephone and cabling
installations and maintenance. There were no charges under this
agreement for the three and nine months ended December 31,
2008.
MANUFACTURING
AGREEMENT
ADM and
Ivivi are parties to a manufacturing agreement, dated as of August 15, 2001, and
as amended in February, 2005. Under the terms of the agreement, ADM has agreed
to serve as the exclusive manufacturer of all current and future medical and
nonmedical electronic and other electronics or products to be sold or rented by
Ivivi. For each product that ADM manufactures, Ivivi pays ADM an amount equal to
120% of the sum of (i) the actual, invoiced cost for raw materials, parts,
components or other physical items that are used in the manufacture of the
product and actually purchased for such entity by ADM, if any, plus (ii) a labor
charge based on ADM's standard hourly manufacturing labor rate, which ADM
believes is more favorable than could be attained from unaffiliated third
parties. Under the terms of the agreement, if ADM is unable to perform its
obligations to Ivivi under the manufacturing agreement or is otherwise in breach
of any provision of the manufacturing agreement, Ivivi has the right, without
penalty, to engage third parties to manufacture some or all of its products. In
addition, if Ivivi elects to utilize a third-party manufacturer to supplement
the manufacturing being completed by ADM, Ivivi has the right to require ADM to
accept delivery of its products from these third-party manufacturers, finalize
the manufacture of the products to the extent necessary and ensure that the
design, testing, control, documentation and other quality assurance procedures
during all aspects of the manufacturing process have been met.
Pursuant
to the manufacturing agreement, sales and manufacturing charges to Ivivi during
the three and nine months ended December 31, 2008 and December 31, 2007 were
approximately $2,896 and $247,799, and $517,823 and $459,702,
respectively.
NOTE
9 – ACQUISITIONS
On August
27, 2008, we acquired all of the assets of Action Spas, a manufacturer of
electronic controllers for spas and hot tubs, under our fully owned subsidiary
Action Industries Unlimited, LLC (“Action”) for $265,000. From this
date, all of the operations of Action are included in our consolidated financial
statements. We acquired Action to continue to expand our electronics
segment operations, and for the opportunity to expand its operations into the
OEM market. The fair value assigned to the acquired assets was as
follows:
Inventory
|
|
$ |
19,184 |
|
Equipment
|
|
|
9,140 |
|
Non-Compete
Agreement
|
|
|
50,000 |
|
Controller
design
|
|
|
100,000 |
|
Customer
list
|
|
|
62,491 |
|
Total
|
|
$ |
240,815 |
|
The
remaining costs were expensed.
The
following table shows the Company’s pro forma unaudited operating revenue, net
loss and loss per share, assuming the acquisition of Action Spas had been made
April 1, 2008:
|
|
|
Nine
Months Ended
|
|
|
|
|
December
31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
1,348,221
|
|
|
Net
Loss
|
|
$
|
(8,445,623
|
)
|
|
Net
loss per share
|
|
|
(0.16
|
)
|
NOTE
10 – NOTE PAYABLE, BANK
On August
21, 2008, the Company entered into a note payable with a commercial bank in the
amount of $200,000. This note bears interest at a rate of 2.98% and
is secured by cash on deposit with the institution, which is classified as
restricted cash. Amounts outstanding under the note are payable on
demand, and interest is payable monthly.
The
following discussion of our operations and financial condition should be read in
conjunction with the consolidated financial statements and notes thereto
included elsewhere in this Quarterly Report on Form 10-Q.
FORWARD-LOOKING
STATEMENTS
This
Quarterly Report on Form 10-Q contains forward-looking statements within the
meaning of the "safe harbor" provisions under section 21E of the Securities and
Exchange Act of 1934 and the Private Securities Litigation Act of 1995. We use
forward-looking statements in our description of our plans and objectives for
future operations and assumptions underlying these plans and objectives.
Forward-looking terminology includes the words "may", "expects", "believes",
"anticipates", "intends", "forecasts", "projects", or similar terms, variations
of such terms or the negative of such terms. These forward-looking statements
are based on management's current expectations and are subject to factors and
uncertainties which could cause actual results to differ materially from those
described in such forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained in this Form 10-Q to reflect any change in
our expectations or any changes in events, conditions or circumstances on which
any forward-looking statement is based. Factors which could cause such results
to differ materially from those described in the forward-looking statements
include those set forth under "Item. 1 Description of Business – Risk Factors"
and elsewhere in or incorporated by reference into our Annual Report on Form
10-KSB for the fiscal year ended March 31, 2008.
CRITICAL
ACCOUNTING POLICIES
REVENUE
RECOGNITION:
CHEMICALS:
Revenues are recognized when products
are shipped to end users. Shipments to distributors are recognized as
sales where no right of return exists.
ELECTRONICS:
We
recognize revenue from the sale of our electronic products when they are shipped
to the purchaser. Revenue from the sale of the electronics we
manufacture for Ivivi is recognized upon completion of the manufacturing
process. Shipping and handling charges and costs are immaterial. We
offer a limited 5 year warranty on our spa/hot tub controller
units. We have no other post shipment obligations and sales returns
have been immaterial.
USE
OF ESTIMATES:
Our
discussion and analysis of our financial condition and results of operations is
based upon our financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States of America. The
preparation of these consolidated financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosures of contingent assets and
liabilities. On an ongoing basis, we evaluate our estimates, including those
related to reserves, deferred tax assets and valuation allowance, impairment of
long-lived assets, fair value of equity instruments issued to consultants for
services and fair value of equity instruments issued to others. We base our
estimates on historical experience and on various other assumptions that we
believe to be reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or conditions; however, we believe
that our estimates, including those for the above described items, are
reasonable.
BUSINESS
OVERVIEW
ADM is a
corporation that was organized under the laws of the State of Delaware on
November 24, 1969. During the nine months ended December 31, 2008 and
2007, our operations were conducted through ADM itself and its subsidiaries,
Action Industries Unlimited, LLC (formed August 20, 2008) (“Action”), Pegasus
Laboratories, Inc. (“PLI”) and Sonotron Medical Systems, Inc
(“SMS”). Our investment in Ivivi Technologies, Inc. (“Ivivi”) from
October 18, 2006 to March 31, 2008 was reported under the equity method of
accounting, whereby we recognized our share of Ivivi's earnings or losses as
they are incurred. Effective April 1, 2008, we adopted SFAS No. 159
“The Fair Value Option for Financial Assets and Liabilities” with respect to our
investment in Ivivi, whereby we report our investment in Ivivi at fair
value.
We are a
technology-based developer and manufacturer of diversified lines of products in
the following three areas: (1) environmentally safe chemical products for
industrial use, (2) electronic products for numerous industries, including
therapeutic non-invasive electronic medical devices and electronic controllers
for spas and hot tubs, and (3) cosmetic and topical dermatological
products. We have historically derived most of our revenues from the
development, manufacture and sale of chemical products, and, to a lesser extent,
from our electronics and topical dermatological products. Although,
during the three and nine months ended December 31, 2008 and 2007, we derived an
increased amount of our revenue from contract manufacturing of electronics for
Ivivi, we have completed our scheduled production for Ivivi, and have not
received any material additional purchase orders from Ivivi to date. Our
Electronics segment includes our Action and SMS subsidiaries, and our Chemical
segment includes our PLI subsidiary.
RESULTS
OF OPERATIONS FOR THE THREE MONTHS ENDED DECEMBER 31, 2008 AS COMPARED TO
DECEMBER 31, 2007
REVENUES
Revenues
were $257,609 for the three months ended December 31, 2008 as compared to
$496,261 for the three months ended December 31, 2007, a decrease of $238,652,
or 48%. The decrease resulted from declines in sales to existing
chemical customers of approximately $26,361, and, decreased sales of
approximately $243,065 in contract manufacturing for Ivivi partially offset by
increased sales of approximately $24,000 of electronic controllers for spas and
hot tubs being generated by our subsidiary Action. Gross profit was
$74,255, or 29%, for the three months ended December 31, 2008 compared to
$143,319, or 29%, for the three months ended December 31, 2007. The
comparative gross margin for the periods was equal.
OPERATING
LOSS
Loss from
operations for the three months ended December 31, 2008 was $217,536, compared
to a loss from operations for the three months ended December 31, 2007 of
$130,487. Selling, general and administrative expenses increased by $18,100, or
7%, from $273,691 to $291,791, mainly due to increased compensation and health
insurance costs and rent, offset by a decrease in consulting expense and samples
expense. Research and development expenses were zero during the three months
ended December 31, 2008 compared to $115 during the three months ended December
31, 2007, as a result of no research and development activities during the third
quarter of 2008.
NET
LOSS AND NET LOSS PER SHARE
Net loss
for the three months ended December 31, 2008 was $860,999, or $0.02 per share,
compared to a net loss for the three months ended December 31, 2007 of $703,357,
or $0.01 per share. With the adoption of SFAS No. 159, “The Fair Value Option
for Financial Assets and Liabilities”, we recorded a decrease in fair value of
$650,000 with respect to our investment in Ivivi, for the three months ended
December 31, 2008. During the three months ended December 31, 2007,
we recorded an equity method investment loss of $594,446 from our investment in
Ivivi. Net interest income decreased $15,039 to $6,537 in the three
months ended December 31, 2008, from $21,576 in the three months ended December
31, 2007, primarily due to decreased funds invested in a money market account
and lower interest rates on such funds, coupled with the interest expense on our
borrowings under our bank loan
RESULTS
OF OPERATIONS FOR THE NINE MONTHS ENDED DECEMBER 31, 2008 AS COMPARED TO
DECEMBER 31, 2007
REVENUES
Revenues
were $1,248,140 for the nine months ended December 31, 2008 as compared to
$1,189,194 for the nine months ended December 31, 2007, an increase of $58,946,
or 5%. This increase was mainly the result of approximately $60,000
greater sales in contract manufacturing for Ivivi and approximately $31,000 in
sales of electronic controllers for spas and hot tubs, being generated by our
subsidiary Action, which were partially offset by declines in sales to our
existing chemical customers of approximately $49,000. Gross profit
was $407,305, or 33%, for the nine months ended December 31, 2008 compared to
$417,023, or 35%, for the nine months ended December 31, 2007. Gross
margins decreased as a result of margins on approximately $517,823 of sales of
electronics at approximately 17% to Ivivi, as compared to margins achieved from
chemical and spa controller product lines, which are generally
higher.
OPERATING
LOSS
Loss from
operations for the nine months ended December 31, 2008 was $485,067, compared to
a loss from operations for the nine months ended December 31, 2007 of $354,850.
Selling, general and administrative expenses increased by $124,164, or 16%, from
$768,208 to $892,372, mainly due to increased compensation costs, health
insurance rates, reduced cost allocations to Ivivi, and the implementation of
a
new
accounting software system offset by a decrease in accounting fees and
consulting fees. Research and development expenses decreased by $3,665, or 100%,
from $3,665 to zero, as a result of no research and development activities
during the first three quarters of 2009.
NET
LOSS AND NET LOSS PER SHARE
Net loss
for the nine months ended December 31, 2008 was $8,489,701, or $0.16 per share,
compared to a net loss for the nine months ended December 31, 2007 of
$1,957,354, or $0.04 per share. With the adoption of SFAS No. 159 “The Fair
Value Option for Financial Assets and Liabilities”, we recorded a decrease in
fair value of $10,465,000 with respect to our investment in Ivivi, for the nine
months ended December 31, 2008. During the nine months ended December
31, 2007, we recorded an equity method investment loss of $1,674,870 from our
investment in Ivivi. Net interest income decreased $37,188 to $35,178
during the nine months ended December 31, 2008, from $72,366 in the nine months
ended December 31, 2007, primarily due to decreased funds invested in a money
market account and lower interest rates on such funds, coupled with the interest
expense on our borrowings under our bank loan. Income tax credits of
$2,425,188 were recognized during the nine months ended December 31, 2008, as a
result of the decrease in fair value of our investment in Ivivi.
LIQUIDITY
AND CAPITAL RESOURCES
At
December 31, 2008, we had cash and equivalents of $1,325,511 as compared to
$2,072,325 at March 31, 2008. The $746,814 decrease was primarily the result of
our loss from operations during the nine month period and $225,000 of cash that
was placed on restriction in connection with the bank loan. To a
lesser extent our cash was reduced by the investment we made to acquire Action
Spas. Our cash will continue to be used for increased marketing
costs, and the related administrative expenses, in order to attempt to increase
our revenue. We expect to have enough cash to fund operations for the
next twelve months. The market value of our investment in Ivivi at
December 31, 2008 was $910,000. However, our common shares of Ivivi have not
been registered with the SEC and are subject to restriction as a result of
securities laws.
OPERATING
ACTIVITIES
Net cash
used by operating activities was $517,241 for the nine months ended December 31,
2008, as compared to net cash used by operating activities of $304,546 for the
nine months ended December 31, 2007. The use of cash during the nine
months ended December 31, 2008 was primarily due to a net loss of $8,489,701,
recognition of a deferred tax benefit of $2,425,188 and decreases in operating
liabilities of $289,001, which was primarily offset by a change in the fair
market value of our investment in Ivivi of $10,465,000 and a decrease in net
operating assets of $199,170. The use of cash during the nine months
ended December 31, 2007 was primarily due to a net loss of $1,957,354 and an
increase in net operating assets of $446,771, which was primarily offset by a
non-cash charge for the equity investment loss in Ivivi of $1,674,870 and
increases in operating liabilities of $413,355.
INVESTING
ACTIVITIES
For the
nine months ended December 31, 2008, net cash used by investing activities was
$429,573. The primary use of cash was for our acquisition of Action
Spas, whereby we acquired intangible assets of $200,000, property and equipment
of $14,888, and $225,000 in operating cash pledged for collateral on borrowings
under our bank loan. Uses of cash were partially offset by
collections from related parties of $23,456, which was received from an officer
for repayment of advances made prior to 2000. For the nine months
ended December 31, 2007, cash used in investing activities was
$2,140. Of this amount, $22,140 was used for the purchase of property
and equipment and $20,000 was received from an officer for repayment of advances
made prior to 2000.
FINANCING
ACTIVITIES
During
the nine months ended December 31, 2008, we borrowed $200,000 from a commercial
bank to facilitate our acquisition of Action Spas. There was no such
activity during the nine months ended December 31, 2007.
OFF
BALANCE SHEET ARRANGEMENTS
We have
no off-balance sheet arrangements that have had or are reasonably likely to have
a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital
expenditures or capital resources.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Concentration
of Credit Risk
Financial
instruments that potentially subject us to significant concentrations of credit
risk consist primarily of cash and cash equivalents, accounts receivable and our
investment in Ivivi. The Company has no control over the market value of its
investment in Ivivi.
We
maintain cash and cash equivalents with well-capitalized financial
institutions.
Our sales
are materially dependent on a small group of customers, as noted in Note 6 of
our financial statements. We monitor our Credit risk associated with our
receivables on a routine basis. We also maintain credit controls for evaluating
and granting customer credit.
ITEM
4T. CONTROLS AND PROCEDURES
EVALUATION
OF DISCLOSURE CONTROLS AND PROCEDURES
We
maintain disclosure controls and procedures (as such term is defined in Rules
13a-15(e) and 15d - 15(e) under the Securities Exchange Act of 1934, as amended
(the "Exchange Act")) that are designed to ensure that information required to
be disclosed in our Exchange Act reports is
recorded,
processed, summarized and reported within the time periods specified in the
Securities and Exchange Commission's rules and forms, and that such information
is accumulated and communicated to management, including the Chief Executive
Officer and Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure. Management necessarily applies its
judgment in assessing the costs and benefits of such controls and procedures,
which, by their nature, can provide only reasonable assurance regarding
management's control objectives.
As of the
end of the period covered by this Quarterly Report on Form 10-Q, we carried out
an evaluation, with the participation of our management, including our Chief
Executive Officer and Chief Financial Officer, of the effectiveness of our
disclosure controls and procedures pursuant to Securities Exchange Act Rule
13a-15. Based on that evaluation as of December 31, 2008, the
Company's principal executive officer and principal financial officer concluded
that the Company's disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) were
effective, as of the date of their evaluation, to ensure that the information
required to be disclosed by the Company in the reports that it files or submits
under the Securities Exchange Act of 1934 is recorded, processed, summarized and
reported within the time periods specified in SEC rules and forms.
CHANGES
IN INTERNAL CONTROLS OVER FINANCIAL REPORTING.
There
were no changes in the our internal control over financial reporting that
occurred during our last fiscal quarter to which this report relates that have
materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
PART
II. OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS.
ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None
ITEM
3. DEFAULTS UPON SENIOR SECURITIES
None
ITEM
4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
ITEM
5. OTHER INFORMATION
None
ITEM
6. EXHIBITS.
(a)
Exhibit No.
31.1
Certification of Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
31.2
Certification of Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
32.1
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
ADM
TRONICS UNLIMITED, INC.
(Registrant)
|
|
By:
|
/s/
Andre' DiMino
|
|
|
|
|
Andre'
DiMino, Chief Executive
|
|
|
|
|
Officer
and Chief Financial Officer
|
|
Dated:
|
Northvale,
New Jersey
|
|
|
|
|
February
23, 2009
|
|
|
|
14